MX2016013245A - Regimen de dosificacion de liberacion inmediata de moduladores s1p. - Google Patents
Regimen de dosificacion de liberacion inmediata de moduladores s1p.Info
- Publication number
- MX2016013245A MX2016013245A MX2016013245A MX2016013245A MX2016013245A MX 2016013245 A MX2016013245 A MX 2016013245A MX 2016013245 A MX2016013245 A MX 2016013245A MX 2016013245 A MX2016013245 A MX 2016013245A MX 2016013245 A MX2016013245 A MX 2016013245A
- Authority
- MX
- Mexico
- Prior art keywords
- immediate release
- release dosage
- modulator
- dosage regimen
- siponimod
- Prior art date
Links
- 239000012729 immediate-release (IR) formulation Substances 0.000 title abstract 2
- KIHYPELVXPAIDH-HNSNBQBZSA-N 1-[[4-[(e)-n-[[4-cyclohexyl-3-(trifluoromethyl)phenyl]methoxy]-c-methylcarbonimidoyl]-2-ethylphenyl]methyl]azetidine-3-carboxylic acid Chemical compound CCC1=CC(C(\C)=N\OCC=2C=C(C(C3CCCCC3)=CC=2)C(F)(F)F)=CC=C1CN1CC(C(O)=O)C1 KIHYPELVXPAIDH-HNSNBQBZSA-N 0.000 abstract 3
- 229950005693 siponimod Drugs 0.000 abstract 2
- 208000023275 Autoimmune disease Diseases 0.000 abstract 1
- 239000002552 dosage form Substances 0.000 abstract 1
- 238000012423 maintenance Methods 0.000 abstract 1
- 238000004448 titration Methods 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/397—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having four-membered rings, e.g. azetidine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2013—Organic compounds, e.g. phospholipids, fats
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2013—Organic compounds, e.g. phospholipids, fats
- A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Neurology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Molecular Biology (AREA)
- Biophysics (AREA)
- Psychiatry (AREA)
- Hospice & Palliative Care (AREA)
- Immunology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201461977816P | 2014-04-10 | 2014-04-10 | |
| PCT/IB2015/052550 WO2015155709A1 (en) | 2014-04-10 | 2015-04-08 | S1p modulator immediate release dosage regimen |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2016013245A true MX2016013245A (es) | 2017-01-16 |
Family
ID=52988364
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2016013245A MX2016013245A (es) | 2014-04-10 | 2015-04-08 | Regimen de dosificacion de liberacion inmediata de moduladores s1p. |
Country Status (16)
| Country | Link |
|---|---|
| US (4) | US20170027907A1 (enExample) |
| EP (3) | EP3129020A1 (enExample) |
| JP (1) | JP6674903B2 (enExample) |
| KR (2) | KR20220156981A (enExample) |
| CN (2) | CN106456552A (enExample) |
| AU (2) | AU2015246036A1 (enExample) |
| CA (1) | CA2943598C (enExample) |
| CL (1) | CL2016002562A1 (enExample) |
| IL (2) | IL305337A (enExample) |
| MX (1) | MX2016013245A (enExample) |
| PH (1) | PH12016501965A1 (enExample) |
| RU (2) | RU2020107732A (enExample) |
| SG (1) | SG11201607894RA (enExample) |
| TW (1) | TW201622721A (enExample) |
| WO (1) | WO2015155709A1 (enExample) |
| ZA (1) | ZA201606519B (enExample) |
Families Citing this family (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| NO2699580T3 (enExample) | 2014-01-24 | 2018-02-24 | ||
| TW201622721A (zh) * | 2014-04-10 | 2016-07-01 | 諾華公司 | Ｓ１ｐ調節劑之立即釋放劑量療法 |
| US11629124B2 (en) | 2017-03-09 | 2023-04-18 | Novartis Ag | Solid forms comprising an oxime ether compound, compositions and methods of use thereof |
| US11434200B2 (en) | 2017-03-09 | 2022-09-06 | Novartis Ag | Solid forms comprising an oxime ether compound and a coformer, compositions and methods of use thereof |
| EP3687530A1 (en) * | 2017-09-29 | 2020-08-05 | Novartis AG | Dosing regimen of siponimod |
| WO2019064217A1 (en) * | 2017-09-29 | 2019-04-04 | Novartis Ag | DOSAGE DIAGRAM OF SIPONIMOD |
| HRP20250115T1 (hr) * | 2018-03-01 | 2025-05-23 | Astrazeneca Ab | Farmaceutski pripravci koji sadrže (2s)-{(1s)-1-cijano-2-[4-(3-metil-2-okso-2,3-dihidro-1,3-benzoksazol-5-il)fenil]etil} -1,4-oksazepan-2-karboksamid |
| CA3106269A1 (en) | 2018-07-17 | 2020-01-23 | Insmed Incorporated | Certain (2s)-n-[(1s)-1-cyano-2-phenylethyl]-1,4-oxazepane-2-carboxamides for treating lupus nephritis |
| CN109908095A (zh) * | 2019-04-08 | 2019-06-21 | 肇庆学院 | 一种西尼莫德片剂及制备方法 |
| MX2022005014A (es) | 2019-10-31 | 2022-05-16 | Idorsia Pharmaceuticals Ltd | Combinacion de un antagonista de cxcr7 con un modulador del receptor s1p1. |
| US11135197B2 (en) | 2020-02-07 | 2021-10-05 | Argentum Pharmaceuticals Llc | Dosage regimen of an S1P receptor modulator |
| EP4646265A1 (en) | 2023-01-06 | 2025-11-12 | Insmed Incorporated | Novel, reversible dpp1 inhibitors and uses thereof |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR20160064245A (ko) * | 2008-12-18 | 2016-06-07 | 노파르티스 아게 | 1-［4-［1-(4-시클로헥실-3-트리플루오로메틸-벤질옥시이미노)-에틸］-2-에틸-벤질］-아제티딘-3-카르복실산의 헤미푸마레이트 염 |
| DK2379069T3 (en) * | 2008-12-22 | 2015-06-08 | Novartis Ag | Dosage Plan for an S1P receptor agonist |
| LT3453387T (lt) * | 2008-12-22 | 2020-08-25 | Novartis Ag | S1p receptoriaus antagonisto dozavimo režimas |
| SG178987A1 (en) * | 2009-09-29 | 2012-04-27 | Novartis Ag | Dosage regimen of an s1p receptor modulator |
| HRP20191842T1 (hr) * | 2011-01-07 | 2019-12-27 | Novartis Ag | Formulacije imunosupresiva |
| WO2012095853A1 (en) | 2011-01-10 | 2012-07-19 | Novartis Pharma Ag | Modified release formulations comprising sip receptor modulators |
| CN103889408A (zh) * | 2011-10-21 | 2014-06-25 | 诺华股份有限公司 | S1p受体调节剂或激动剂的剂量方案 |
| TW201622721A (zh) * | 2014-04-10 | 2016-07-01 | 諾華公司 | Ｓ１ｐ調節劑之立即釋放劑量療法 |
-
2015
- 2015-04-08 TW TW104111330A patent/TW201622721A/zh unknown
- 2015-04-08 CN CN201580031360.0A patent/CN106456552A/zh active Pending
- 2015-04-08 EP EP15717256.0A patent/EP3129020A1/en not_active Withdrawn
- 2015-04-08 EP EP20215763.2A patent/EP3831378A1/en not_active Withdrawn
- 2015-04-08 MX MX2016013245A patent/MX2016013245A/es unknown
- 2015-04-08 SG SG11201607894RA patent/SG11201607894RA/en unknown
- 2015-04-08 CA CA2943598A patent/CA2943598C/en active Active
- 2015-04-08 EP EP21212400.2A patent/EP4074312A1/en active Pending
- 2015-04-08 WO PCT/IB2015/052550 patent/WO2015155709A1/en not_active Ceased
- 2015-04-08 KR KR1020227039781A patent/KR20220156981A/ko not_active Ceased
- 2015-04-08 AU AU2015246036A patent/AU2015246036A1/en not_active Abandoned
- 2015-04-08 RU RU2020107732A patent/RU2020107732A/ru unknown
- 2015-04-08 KR KR1020167031062A patent/KR20160141841A/ko not_active Ceased
- 2015-04-08 JP JP2016561731A patent/JP6674903B2/ja active Active
- 2015-04-08 US US15/300,989 patent/US20170027907A1/en not_active Abandoned
- 2015-04-08 IL IL305337A patent/IL305337A/en unknown
- 2015-04-08 CN CN202310667400.7A patent/CN116650467A/zh active Pending
- 2015-04-08 RU RU2016143979A patent/RU2715734C2/ru not_active Application Discontinuation
-
2016
- 2016-09-21 ZA ZA2016/06519A patent/ZA201606519B/en unknown
- 2016-09-22 IL IL247986A patent/IL247986A0/en unknown
- 2016-10-04 PH PH12016501965A patent/PH12016501965A1/en unknown
- 2016-10-07 CL CL2016002562A patent/CL2016002562A1/es unknown
-
2018
- 2018-08-21 US US16/106,072 patent/US20190054065A1/en not_active Abandoned
-
2020
- 2020-05-12 AU AU2020203107A patent/AU2020203107B2/en active Active
- 2020-06-02 US US16/890,722 patent/US20220016076A1/en not_active Abandoned
-
2024
- 2024-10-23 US US18/924,230 patent/US20250041266A1/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| TW201622721A (zh) | 2016-07-01 |
| IL305337A (en) | 2023-10-01 |
| EP3129020A1 (en) | 2017-02-15 |
| AU2020203107B2 (en) | 2021-10-21 |
| JP2017510607A (ja) | 2017-04-13 |
| CA2943598C (en) | 2023-03-07 |
| CA2943598A1 (en) | 2015-10-15 |
| AU2015246036A1 (en) | 2016-10-13 |
| US20220016076A1 (en) | 2022-01-20 |
| SG11201607894RA (en) | 2016-10-28 |
| JP6674903B2 (ja) | 2020-04-01 |
| EP4074312A1 (en) | 2022-10-19 |
| PH12016501965A1 (en) | 2017-01-09 |
| US20170027907A1 (en) | 2017-02-02 |
| KR20220156981A (ko) | 2022-11-28 |
| IL247986A0 (en) | 2016-11-30 |
| CL2016002562A1 (es) | 2017-07-28 |
| RU2715734C2 (ru) | 2020-03-03 |
| CN116650467A (zh) | 2023-08-29 |
| KR20160141841A (ko) | 2016-12-09 |
| RU2016143979A3 (enExample) | 2018-11-12 |
| WO2015155709A1 (en) | 2015-10-15 |
| RU2020107732A (ru) | 2020-03-30 |
| EP3831378A1 (en) | 2021-06-09 |
| ZA201606519B (en) | 2017-11-29 |
| CN106456552A (zh) | 2017-02-22 |
| US20250041266A1 (en) | 2025-02-06 |
| US20190054065A1 (en) | 2019-02-21 |
| AU2020203107A1 (en) | 2020-05-28 |
| RU2016143979A (ru) | 2018-05-14 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| PH12016501965A1 (en) | S1p modulator immediate release dosage regimen | |
| SG10201806787VA (en) | Modulators of complement factor b | |
| PH12014501997A1 (en) | Esketamine for the treatment of treatment-refractory or treatment-resistant depression | |
| PH12017500746A1 (en) | Carbidopa and l-dopa prodrugs and their use to treat parkinson's disease | |
| MX2015016983A (es) | Moduladores del transporte nuclear y usos de los mismos. | |
| PH12017500933A1 (en) | Sublingual administration of riluzole | |
| EP3141603A4 (en) | Gpc3-targeted therapeutic agent for administration to patients for whom gpc3-targeted therapeutic agent therapy is effective | |
| MX356728B (es) | Combinación farmacéutica para usar en el tratamiento de pacientes que padecen diabetes de tipo 2. | |
| PH12017500934B1 (en) | Sublingual formulation of riluzole | |
| MX2018000546A (es) | Composiciones farmaceuticas que contienen celecoxib y tramadol. | |
| MX2016006087A (es) | Formulaciones de desintegracion rapida y metodos de uso. | |
| MX367926B (es) | Composicion farmaceutica para liberacion sostenida de lanreotida. | |
| PH12016502233A1 (en) | (s)-pirlindole or its pharmaceutically acceptable salts for use in medicine | |
| MY175326A (en) | Product and method for treating diarrhea | |
| MX2017000472A (es) | Combinacion de extracto de raiz de valeriana y aceite de lavanda para su utilizacion en el tratamiento de trastornos del sueño. | |
| MX2016006544A (es) | Witanolidos utiles para el tratamiento de enfermedades neurodegenerativas. | |
| NZ709664A (en) | Use of fenugreek extract to enhance female libido | |
| PH12017500923A1 (en) | New dosage and use of a a2a antagonist | |
| MX369774B (es) | Uso de pregn-4-en-20-in-3-ona para el tratamiento de trastornos depresivos. | |
| TR201903234T4 (tr) | Parkinson hastalığının tedavisinde kullanılmaya yönelik dopamin içeren farmasötik çözelti. | |
| RU2014154366A (ru) | Применение пробиотического штамма микроорганизма enterococcus faecium l3 для лечения нейродегенеративных заболеваний | |
| EA201491939A1 (ru) | Модуляторы прогестероновых рецепторов для применения в профилактике или лечении болезней, опосредованных андрогенами | |
| UA90321U (uk) | Спосіб лікування дисбіозу товстої кишки у хворих на віл-інфекцію/снід | |
| UA74055U (ru) | Способ хирургического лечения рефрактерных форм глаукомы | |
| UA95253U (uk) | Спосіб підсилення аналгетичної дії периферичного ґенезу карбамазепіну |